Genomic Data Collection Encouraged, But Not Mandated, For Early Clinical Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA draft guidance emphasizes importance of pre-specifying DNA sample collection at the start of a clinical program.
You may also be interested in...
FDA Prepares To Begin Search For Safety Issues At Molecular Level
FDA is exploring a pharmacological approach for identifying a drug's safety characteristics so sponsors can assess risk earlier in the drug development process
KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
Amgen feels the sales impact from excluding KRAS-positive patients from Vectibix treatment has already occurred, but the firms plans to co-market a test kit shortly.
Tissue Samples Will Play Important Role In Identifying Predictive Biomarkers
Patient tissue samples will be a crucial element in the development of companion diagnostics, the Oncologic Drugs Advisory Committee predicted at its Dec. 16 meeting